secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001641172-25-022791
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M
-----------------------------------------------------------------------------

- Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.
- Cash $5.3M at June 30, 2025, down from $9.6M at Dec 31, 2024; restricted cash $0.1M.
- FDA Fast Track Designation granted for CLD-201 for soft tissue sarcoma; Phase 1 IND opened Q1 2025.
- Raised $4.6M gross proceeds via warrant inducement; total 2025 raises $15.7M.
- Preclinical data for CLD-401 (RedTail platform) presented at ASCO; IND expected by end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/0001641172-25-022791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer